Free Trial
NASDAQ:NEPH

Nephros (NEPH) Stock Price, News & Analysis

Nephros logo
$2.03 +0.22 (+12.15%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$1.92 -0.11 (-5.62%)
As of 04/2/2025 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Nephros Stock (NASDAQ:NEPH)

Key Stats

Today's Range
$1.82
$2.04
50-Day Range
$1.41
$2.03
52-Week Range
$1.36
$2.55
Volume
42,648 shs
Average Volume
12,912 shs
Market Capitalization
$21.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Remove Ads

Nephros Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

NEPH MarketRank™: 

Nephros scored higher than 32% of companies evaluated by MarketBeat, and ranked 786th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nephros has received no research coverage in the past 90 days.

  • Read more about Nephros' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nephros is -22.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nephros is -22.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nephros has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Nephros' valuation and earnings.
  • Percentage of Shares Shorted

    0.21% of the float of Nephros has been sold short.
  • Short Interest Ratio / Days to Cover

    Nephros has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nephros has recently increased by 133.73%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nephros does not currently pay a dividend.

  • Dividend Growth

    Nephros does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.21% of the float of Nephros has been sold short.
  • Short Interest Ratio / Days to Cover

    Nephros has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nephros has recently increased by 133.73%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Nephros has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Nephros this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Nephros insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.10% of the stock of Nephros is held by insiders.

  • Percentage Held by Institutions

    41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nephros' insider trading history.
Receive NEPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter.

NEPH Stock News Headlines

Nephros Full Year 2024 Earnings: Beats Expectations
Trump… a socialist?
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Pleasing Signs As A Number Of Insiders Buy Nephros Stock
See More Headlines

NEPH Stock Analysis - Frequently Asked Questions

Nephros' stock was trading at $1.47 at the beginning of the year. Since then, NEPH stock has increased by 38.1% and is now trading at $2.03.
View the best growth stocks for 2025 here
.

Nephros, Inc. (NASDAQ:NEPH) issued its earnings results on Monday, March, 24th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.01) by $0.04. The business had revenue of $3.87 million for the quarter, compared to analysts' expectations of $3.67 million. Nephros had a negative trailing twelve-month return on equity of 11.39% and a negative net margin of 6.86%.

Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nephros investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Jabil (JBL), Arista Networks (ANET), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
3/24/2025
Today
4/03/2025
Next Earnings (Estimated)
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NEPH
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+146.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-1,580,000.00
Pretax Margin
-6.86%

Debt

Sales & Book Value

Annual Sales
$14.16 million
Price / Cash Flow
N/A
Book Value
$0.80 per share
Price / Book
2.54

Miscellaneous

Free Float
10,112,000
Market Cap
$21.52 million
Optionable
Not Optionable
Beta
1.19
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:NEPH) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners